Aspirin use can greatly benefit patients with breast cancer, according to a study published in Medicine.

In this meta-analysis, the investigators searched PubMed, EMBASE, and other databases for literature pertaining to the relationship between aspirin use and breast cancer prognosis. The article publishing cutoff for the search was specified as October 2019. The related results of all-cause death, breast cancer-specific death, and breast cancer recurrence or metastasis were extracted to combine the effect amount, the researchers noted. In total, the analysis included 13 papers, consisting of 142,644 patients diagnosed with breast cancer.

The results of meta-analysis showed that aspirin use was correlated with lower breast cancer-specific death (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.61-0.76), all-cause death (HR, 0.78; 95% CI, 0.71-0.84), and risk of recurrence/metastasis (HR, 0.91; 95% CI, 0.82-1.00).

“Aspirin use may improve all-cause mortality, specific mortality, and risk of recurrence/metastasis in patients with breast cancer,” the researchers concluded.

Read more at:


Keywords: Aspirin, metastasis, breast cancer